Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial and Operational Results – Yahoo Finance

Posted on March 19, 2012 by admin

The “410 trial” is a Phase 1/2 trial in combination with sunitinib in patients with renal cell carcinoma, gastrointestinal stromal tumors or pancreatic neuroendocrine tumors. To date, across all clinical trials, TH-302 has been administered to … Bing News – Full Story →

Share

Related posts:

  1. NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance – Yahoo Finance
  2. Cyclacel Pharmaceuticals to Announce Year End & Fourth Quarter 2010 Financial Results and Presentation at Upcoming Conference – msnbc.com
  3. Chelsea Therapeutics Reports Second Quarter 2011 Results – Yahoo Finance
  4. XenoPort Reports Third Quarter Financial Results – Yahoo Finance
  5. XenoPort Reports Second Quarter Financial Results – Marketwatch
This entry was posted in Intestinal Cancer and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>